The digital press release with multimedia content can be accessed here: Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta ® ...

Copenhagen, Denmark; August 20, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of Kesimpta ® (ofatumumab) injection for ...

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...

Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses. Novartis presented study data at the sixth annual ...

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of ...

People with relapsing-remitting and active secondary-progressive multiple sclerosis (MS), as well as those with clinically isolated syndrome (CIS, an initial neurological episode), have a new ...

Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (ofatumumab) ...

EAST HANOVER, N.J., Aug. 20, 2020 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for ...

The MarketWatch News Department was not involved in the creation of this content. -- ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in ...

Kesimpta® (ofatumumab) approved by U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adults First B-cell therapy that can be self-administered using Sensoready® autoinjector pen ...